{"drugs":["AK-Dilate","Mydfrin","Neo-Synephrine","Neofrin","Nostril","Ocu-Phrin","Phenylephrine Hydrochloride","Prefrin Liquifilm","Vicks Sinex"],"mono":{"0":{"id":"464840-s-0","title":"Generic Names","mono":"Phenylephrine Hydrochloride"},"1":{"id":"464840-s-1","title":"Dosing and Indications","sub":[{"id":"464840-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Glaucoma:<\/b> (open-angle glaucoma) instill 1 drop of 2.5% ophthalmic solution TOPICALLY on the upper limbus of affected eye(s) a few minutes after application of topical anesthetic; may repeat after 1 hour<\/li><li><b>Hypotension, During anesthesia:<\/b> (during anesthesia) initial dose, 40 to 100 mcg via IV bolus, then every 1 to 2 minutes as needed; MAX total dose 200 mcg  OR initial, 50 to 100 mcg IV bolus (range, 50 to 250 mcg)<\/li><li><b>Hypotension, During anesthesia:<\/b> (during anesthesia) blood pressure below target goal, 10 to 35 mcg\/min continuous IV infusion; MAX 200 mcg\/min  OR 0.5 to 1.4 mcg\/kg\/min continuous IV infusion; titrate to blood pressure goal<\/li><li><b>Hypotension, During anesthesia; Prophylaxis:<\/b> 2 to 3 mg SUBQ or IM 3 to 4 min before injection of spinal anesthetic<\/li><li><b>Hypotension - Shock:<\/b> 0.5 to 6 mcg\/kg\/min IV continuous infusion, titrate to blood pressure goal; no increase in efficacy above 6 mcg\/kg\/min<\/li><li><b>Mydriasis induction:<\/b> (vasoconstriction and pupil dilation) instill 1 drop of 2.5% ophthalmic solution TOPICALLY on the upper limbus of affected eye(s) a few minutes after application of topical anesthetic; may repeat after 1 hour<\/li><li><b>Mydriasis induction:<\/b> (ophthalmoscopic examination) 1 drop of 2.5% solution instilled TOPICALLY in each eye 15 to 30 minutes prior to examination<\/li><li><b>Mydriasis induction:<\/b> (refraction) 1 drop of 2.5% solution instilled TOPICALLY in each eye 5 min after instillation of 1 drop of preferred cycloplegic in each eye<\/li><li><b>Mydriasis induction:<\/b> (blanching test) 1 to 2 drops of 2.5% solution instilled TOPICALLY in the injected eye<\/li><li><b>Mydriasis induction:<\/b> (preoperative) 1 drop of 2.5% solution instilled TOPICALLY in each eye 30 to 60 minutes prior to surgery<\/li><li><b>Nasal congestion, Nasal formulation:<\/b> 2 to 3 drops or sprays of 0.25% to 0.5% NASAL solution into each nostril every 4 hour as needed<\/li><li><b>Nasal congestion, Oral formulation:<\/b> 10 mg to 20 mg ORALLY every 4 hours<\/li><li><b>Paroxysmal supraventricular tachycardia:<\/b> initial, up to 0.5 mg IV given rapidly within 20 to 30 seconds; additional doses should not be 0.1 mg to 0.2 mg more than preceding dose and should be based on blood pressure; MAX dose 1 mg<\/li><li><b>Posterior synechiae - Uveitis:<\/b> 1 drop of 2.5% solution instilled TOPICALLY to upper surface of the cornea, may repeat as necessary, do not exceed 3 applications<\/li><li><b>Regional anesthesia; Adjunct:<\/b> (prolongation of spinal analgesia) 2 to 5 mg added to anesthetic solution<\/li><li><b>Regional anesthesia; Adjunct:<\/b> (vasoconstrictor for regional analgesia) 1 mg added to every 20 mL of anesthetic solution<\/li><\/ul>"},{"id":"464840-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>cough\/cold products should not be used in children younger than 2 years due to the risk of serious and life-threatening effects; phenylephrine is commonly used as an decongestant in combination OTC cough and cold products<\/li><li><b>Hypotension, During anesthesia:<\/b> (during spinal anesthesia) 0.5 mg to 1 mg per every 25 pounds of body weight SUBQ or IM<\/li><li><b>Hypotension, During anesthesia:<\/b> 5 to 20 mcg\/kg IV bolus dose, repeat every 10 to 15 min<\/li><li><b>Hypotension, During anesthesia:<\/b> 0.1 mg\/kg or 3 mg\/m(2) SUBQ or IM as a single dose, repeat every 1 to 2 hour; MAX cumulative dose, 5 mg<\/li><li><b>Mydriasis induction:<\/b> 1 drop of 2.5% ophthalmic solution to the conjunctiva; may repeat in 1 hour if necessary<\/li><li><b>Nasal congestion, Nasal formulation:<\/b> (12 yr and older) 2 to 3 drops or sprays of 0.25% to 0.5% NASAL solution into each nostril every 4 hour as needed<\/li><li><b>Nasal congestion, Nasal formulation:<\/b> (6 to 12 yr) 2 to 3 drops or sprays of 0.25% NASAL solution into each nostril every 4 hour as needed<\/li><li><b>Nasal congestion, Nasal formulation:<\/b> (1 to 6 yr) 2 to 3 drops or sprays of 0.125% NASAL solution into each nostril every 4 hour as needed<\/li><li><b>Nasal congestion, Oral formulation:<\/b> (12 yr and older) 10 mg to 20 mg ORALLY every 4 hours<\/li><li><b>Nasal congestion, Oral formulation:<\/b> (6 to 12 yr) 10 mg ORALLY every 4 hours<\/li><li><b>Nasal congestion, Oral formulation:<\/b> (2 to 6 yr) 5 mg ORALLY every 4 hours<\/li><\/ul>"},{"id":"464840-s-1-6","title":"Dose Adjustments","mono":"<ul><li>renal impairment (ESRD), consider initiation at low end of usual IV dose range; adjust dose based on blood pressure goal<\/li><li>hepatic impairment, liver cirrhosis (Child-Pugh B or C), initiate IV therapy with usual dose, but may need to increase due to decreased responsiveness<\/li><li>geriatric, initiate IV therapy at low end of usual dose range<\/li><li>geriatric, ocular route, use of 2.5% solution recommended<\/li><\/ul>"},{"id":"464840-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Glaucoma<\/li><li>Hypotension, During anesthesia<\/li><li>Hypotension - Shock<\/li><li>Mydriasis induction<\/li><li>Nasal congestion, Nasal formulation<\/li><li>Nasal congestion, Oral formulation<\/li><li>Posterior synechiae - Uveitis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Hypotension, During anesthesia; Prophylaxis<\/li><li>Mydriasis induction, Maintenance<\/li><li>Paroxysmal supraventricular tachycardia<\/li><li>Priapism<\/li><li>Regional anesthesia; Adjunct<\/li><\/ul>"}]},"3":{"id":"464840-s-3","title":"Contraindications\/Warnings","sub":[{"id":"464840-s-3-9","title":"Contraindications","mono":"<ul><li>anatomical narrow-angle<\/li><li>arteriosclerotic cardiovascular or cerebrovascular disease, severe; in infants and elderly<\/li><li>hypersensitivity to phenylephrine products or any of its components<\/li><li>hypertension, severe<\/li><li>intraocular operative procedures with disturbance of corneal epithelial barrier<\/li><li>narrow angle glaucoma<\/li><li>pediatric use<\/li><li>ventricular tachycardia<\/li><\/ul>"},{"id":"464840-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- use extreme caution patients with partial cardiac block, bradycardia, severe arteriosclerosis, and myocardial disease<\/li><li>-- severe bradycardia and decreased cardiac output may occur<\/li><li>-- excessive peripheral and visceral vasoconstriction with ischemia to vital organs may occur, especially in patients with extensive peripheral vascular disease<\/li><li>-- increased blood pressure may occur and precipitate underlying heart failure, angina in patient with severe arteriosclerosis or past history of angina, and  increase pulmonary arterial pressure<\/li><li>-- increased risk of cardiovascular reaction, including ventricular arrhythmia or myocardial infarction, especially in elderly patients; monitoring recommended<\/li><li>-- increased risk of cerebral blood vessel rupture in patients with severe and persistent hypertension<\/li><li>Dermatologic:<\/li><li>-- avoid extravasation as this can cause necrosis or sloughing of tissue<\/li><li>Endocrine and Metabolic:<\/li><li>-- use extreme caution in patients with hyperthyroidism<\/li><li>Immunologic:<\/li><li>-- allergic reactions, including anaphylactic symptoms, may occur in patients with sulfite-sensitivity<\/li><li>Neurologic:<\/li><li>-- blood pressure response to adrenergic drugs may be increased in patients with autonomic dysfunction<\/li><li>Ophthalmic:<\/li><li>-- avoid intraocular use<\/li><li>-- rebound miosis is reported in older patients within one day; caution is advised to monitor for this effect in patients undergoing retinal detachment or cataract surgery<\/li><li>-- transient aqueous pigment floater may develop 30-45 minutes following use of ophthalmic solution in older patients<\/li><li>Other:<\/li><li>-- anesthesia with agents (e.g., trichloroethylene, cyclopropane, halothane) that sensitize the myocardium to sympathomimetics should be used with caution<\/li><li>-- increased risk of vasopressor response with higher than recommended doses, instrumented, traumatized, diseased, or postsurgical eye or adnexa, or with reduced lacrimation during anesthesia<\/li><li>Renal:<\/li><li>-- renal replacement therapy may be required in septic shock patients; monitoring recommended<\/li><\/ul>"},{"id":"464840-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Phenylephrine: C (FDA)<\/li><li>Phenylephrine: B2 (AUS)<\/li><\/ul>"},{"id":"464840-s-3-12","title":"Breast Feeding","mono":"Phenylephrine: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"464840-s-4","title":"Drug Interactions","sub":[{"id":"464840-s-4-13","title":"Contraindicated","mono":"<ul><li>Clorgyline (theoretical)<\/li><li>Iproniazid (probable)<\/li><li>Isocarboxazid (theoretical)<\/li><li>Linezolid (theoretical)<\/li><li>Nialamide (probable)<\/li><li>Phenelzine (theoretical)<\/li><li>Procarbazine (probable)<\/li><li>Rasagiline (theoretical)<\/li><li>Selegiline (theoretical)<\/li><li>Tranylcypromine (theoretical)<\/li><\/ul>"},{"id":"464840-s-4-14","title":"Major","mono":"<ul><li>Amitriptyline (probable)<\/li><li>Amoxapine (probable)<\/li><li>Clomipramine (probable)<\/li><li>Desipramine (probable)<\/li><li>Dothiepin (probable)<\/li><li>Doxepin (probable)<\/li><li>Furazolidone (theoretical)<\/li><li>Imipramine (probable)<\/li><li>Iobenguane I 123 (theoretical)<\/li><li>Lofepramine (probable)<\/li><li>Midodrine (theoretical)<\/li><li>Nortriptyline (probable)<\/li><li>Opipramol (probable)<\/li><li>Pargyline (probable)<\/li><li>Protriptyline (probable)<\/li><li>Trimipramine (probable)<\/li><\/ul>"},{"id":"464840-s-4-15","title":"Moderate","mono":"<ul><li>Guanethidine (probable)<\/li><li>Propranolol (probable)<\/li><\/ul>"}]},"5":{"id":"464840-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Ophthalmic:<\/b>Pain in eye, Transient, ophthalmic solution<\/li><li><b>Respiratory:<\/b>Nasal congestion, Rebound, Nasal stinging\/burning, Sneezing<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Angina, Cardiac dysrhythmia, Decreased cardiac output, Heart failure, Exacerbation, Hypertension, Hypertensive crisis, Ischemia, Myocardial infarction, Peripheral ischemia, Reflex bradycardia<\/li><li><b>Dermatologic:<\/b>Necrosis<\/li><li><b>Gastrointestinal:<\/b>Abdominal angina<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Respiratory:<\/b>Pulmonary edema<\/li><\/ul>"},"6":{"id":"464840-s-6","title":"Drug Name Info","sub":{"0":{"id":"464840-s-6-17","title":"US Trade Names","mono":"<ul><li>Neo-Synephrine<\/li><li>Neofrin<\/li><li>Nostril<\/li><li>Prefrin Liquifilm<\/li><li>Ocu-Phrin<\/li><li>Vicks Sinex<\/li><li>Mydfrin<\/li><li>AK-Dilate<\/li><\/ul>"},"2":{"id":"464840-s-6-19","title":"Class","mono":"<ul><li>Adrenergic<\/li><li>Alkylarylamine<\/li><li>Decongestant<\/li><li>Hemorrhoidal Agent<\/li><li>Mydriatic-Cycloplegic<\/li><li>Sympathomimetic<\/li><li>Vasopressor<\/li><\/ul>"},"3":{"id":"464840-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"464840-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"464840-s-7","title":"Mechanism Of Action","mono":"Phenylephrine hydrochloride, a synthetic sympathomimetic agent, is a powerful postsynaptic alpha-receptor agonist with minimal effect on the beta-receptors of the heart. It exhibits a rapid and moderately extended vasoconstrictor and mydriatic action. Its action in the heart includes elevation of the heart rate and reduction of cardiac output.<br\/>"},"8":{"id":"464840-s-8","title":"Pharmacokinetics","sub":[{"id":"464840-s-8-23","title":"Absorption","mono":"Bioavailability: Oral, 38%.<br\/>"},{"id":"464840-s-8-24","title":"Distribution","mono":"<ul><li>Organs: High distribution<\/li><li>Peripheral tissues: High distribution<\/li><li>Vd, 340 L<\/li><\/ul>"},{"id":"464840-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: Extensive via monoamine oxidase and sulfotransferase<\/li><li>m-Hydroxymandelic acid: Inactive<\/li><\/ul>"},{"id":"464840-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 86%, primarily changed<\/li><li>Total body clearance: 2100 L\/min<\/li><\/ul>"},{"id":"464840-s-8-27","title":"Elimination Half Life","mono":"<ul><li>IV, 1.5 hours<\/li><li>Oral, 2 to 3 hours.<\/li><\/ul>"}]},"9":{"id":"464840-s-9","title":"Administration","mono":"<ul><li><b>Intravenous<\/b><br\/><ul><li>bolus, dilute to 100 mcg\/mL in NS or D5W prior to use (1 mL phenylephrine 10 mg\/mL plus 99 mL NS or D5W)<\/li><li>continuous infusion, dilute to 20 mcg\/mL in NS or D5W prior to use (1 mL phenylephrine 10 mg\/mL in 500 mL NS or D5W)<\/li><li>after dilution, use within 4 hours if stored at room temperature or within 24 hours if refrigerated<\/li><li>correct intravascular volume depletion or acidosis during administration<\/li><li>paroxysmal supraventricular tachycardia, rapid IV bolus injection (within 20 to 30 seconds) is recommended<\/li><\/ul><\/li><li><b>Nasal<\/b><br\/>should not be used for more than 3 days; prolonged use may worsen nasal congestion or cause nasal congestion to recur.<br\/><\/li><li><b>Ophthalmic<\/b><br\/><ul><li>mydriasis, apply to upper limbus following local anesthetic administration; may be repeated<\/li><li>uveitis, posterior synechiae, apply to upper surface of cornea; repeat as necessary up to 3 times<\/li><li>heavily pigmented irides may require larger doses<\/li><\/ul><\/li><li><b>Oral<\/b><br\/>place tablet on tongue; will disintegrate with or without water<br\/><\/li><\/ul>"},"10":{"id":"464840-s-10","title":"Monitoring","mono":"<ul><li>renal function; during therapy, especially patients with septic shock<\/li><li>improvements in hypotension during anesthesia, achieving therapeutic mydriasis, or reduced nasal congestion indicate efficacy<\/li><li>infusion site; assess free flow<\/li><\/ul>"},"11":{"id":"464840-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Injection Solution: 10 MG\/ML<\/li><li>Intravenous Solution: 100 MCG\/ML<\/li><li>Nasal Solution: 1 %<\/li><li>Ophthalmic Solution: 2.5 %, 10 %<\/li><li>Oral Tablet: 10 MG<\/li><\/ul><\/li><li><b>4-Way Fast Acting<\/b><br\/>Nasal Spray: 1 %<br\/><\/li><li><b>4 Way Menthol<\/b><br\/>Nasal Spray: 1 %<br\/><\/li><li><b>4-Way No Drip<\/b><br\/>Nasal Spray: 1 %<br\/><\/li><li><b>Altafrin<\/b><br\/>Ophthalmic Solution: 0.12 %, 2.5 %, 10 %<br\/><\/li><li><b>Anu-Med NF<\/b><br\/>Rectal Suppository: 0.25 %<br\/><\/li><li><b>Children's Sudafed PE Nasal Decongestant<\/b><br\/>Oral Solution: 2.5 MG\/5 ML<br\/><\/li><li><b>Childrens Triaminic Thin Strips<\/b><br\/>Mucous Membrane Film: 2.5 MG<br\/><\/li><li><b>Contac D Cold<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>Despec-SF<\/b><br\/>Oral Liquid: 5 MG\/5 ML<br\/><\/li><li><b>Good Neighbor Pharmacy Nasal Decongestant PE<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>Good Sense Nasal Decongestant PE<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>Good Sense Nasal Four<\/b><br\/>Nasal Spray: 1 %<br\/><\/li><li><b>Leader Nose Drops<\/b><br\/>Nasal Solution: 1 %<br\/><\/li><li><b>Little Noses Decongestant Nose Drops<\/b><br\/>Nasal Solution: 0.125 %<br\/><\/li><li><b>Lusonal<\/b><br\/>Oral Solution: 7.5 MG\/5 ML<br\/><\/li><li><b>Medicone<\/b><br\/>Rectal Suppository: 0.25 %<br\/><\/li><li><b>Medi-First Non-Pseudo Sinus Decongestant<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>Medi-Phenyl<\/b><br\/>Oral Tablet: 5 MG<br\/><\/li><li><b>Nasal Decongestant PE<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>Neofrin<\/b><br\/>Ophthalmic Solution: 2.5 %, 10 %<br\/><\/li><li><b>Neo-Synephrine HCl<\/b><br\/>Injection Solution: 10 MG\/ML<br\/><\/li><li><b>Neo-Synephrine<\/b><br\/><ul><li>Nasal Solution: 0.25 %, 0.5 %, 1 %<\/li><li>Nasal Spray: 0.25 %, 0.5 %, 1 %<\/li><\/ul><\/li><li><b>PediaCare Decongestant Drops<\/b><br\/>Oral Solution: 1.25 MG\/0.8 ML<br\/><\/li><li><b>Pediacare Infant Dropper Decongestant<\/b><br\/>Oral Solution: 1.25 MG\/0.8 ML<br\/><\/li><li><b>Prefrin Liquifilm<\/b><br\/>Ophthalmic Solution: 0.12 %<br\/><\/li><li><b>Quality Choice Suphedrine PE<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>Rectasol<\/b><br\/>Rectal Suppository: 0.25 %<br\/><\/li><li><b>Rhinall<\/b><br\/><ul><li>Nasal Solution: 0.25 %<\/li><li>Nasal Spray: 0.25 %<\/li><\/ul><\/li><li><b>Rite Aid Nasal Decongestant PE<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>Rite Aid Sinus Pressure &amp; Congestion Relief PE<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>Sudafed PE<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>Sudogest PE<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>Sudo-Tab PE<\/b><br\/>Oral Tablet: 5 MG<br\/><\/li><li><b>Sunmark Nasal Decongestant PE<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>The Medicine Shoppe Nasal Decongestant<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>TopCare Nasal Decongestant PE<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>TopCare Nasal Four<\/b><br\/>Nasal Spray: 1 %<br\/><\/li><li><b>TopCare Nose Drops<\/b><br\/>Nasal Solution: 1 %<br\/><\/li><li><b>Vazculep<\/b><br\/>Intravenous Solution: 10 MG\/ML<br\/><\/li><\/ul>"},"12":{"id":"464840-s-12","title":"Toxicology","sub":[{"id":"464840-s-12-31","title":"Clinical Effects","mono":"<b>SYMPATHOMIMETICS-PARENTERAL <\/b><br\/>USES: This class of drugs are used to treat hypotension, bradycardia, heart failure, asthma, and anaphylaxis, which includes epinephrine, norepinephrine, dobutamine, dopamine, isoproterenol, terbutaline, and phenylephrine. PHARMACOLOGY: These agents cause stimulation of adrenergic receptors leading to vasoconstriction, increased inotropy and chronotropy. TOXICOLOGY: Primarily from sympathomimetic excess and can either result from vasoconstriction leading to ischemia and hypoxia in end organs, toxic effects from hypertension or hypotension, and cardiac strain from tachycardia. EPIDEMIOLOGY: Uncommon overdose that can lead to significant morbidity and mortality. OVERDOSE: Overdoses are typically iatrogenic.  Home exposure is generally from accidental injection of epinephrine autoinjectors.  These drugs have occasionally been injected as drugs of abuse, although this is rare. MILD TO MODERATE TOXICITY: Tachycardia, nausea, vomiting, hypertension, headache, diaphoresis, and pallor. SEVERE TOXICITY:  Seizures, stroke, pulmonary edema, hypotension, cyanosis, myocardial ischemia or infarction, dysrhythmias, acidosis, hypokalemia, and tissue necrosis. ADVERSE EFFECTS:  Tachycardia, nausea, vomiting, hypertension, headache, diaphoresis, and pallor. Ischemic necrosis secondary to local vasoconstriction can result from extravasation of sympathomimetic agents including dobutamine, dopamine, epinephrine, metaraminol and norepinephrine. TERBUTALINE: use of terbutaline in pregnant women for the prevention or prolonged treatment (beyond 48 to 72 hours) of preterm labor carries the risk of potentially serious maternal cardiac events (ie, tachycardia, cardiac dysrhythmias, myocardial infarction, hypertension and pulmonary edema) and death. <br\/>"},{"id":"464840-s-12-32","title":"Treatment","mono":"<b>SYMPATHOMIMETICS-PARENTERAL <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Accidental digital or intramuscular injections of epinephrine can usually be managed with warm soaks and compresses.  Other treatments are not well studied, but injections of phentolamine, use of nitroglycerin paste, and injections of terbutaline have been reported to be successful.  Vital signs should be continuously monitored in other parenteral overdoses. Hypertension without evidence of end organ dysfunction should first be treated with benzodiazepines which can reduce adrenergic tone and treat agitation.  Sinus tachycardia generally does not require treatment unless there is evidence of end organ dysfunction. MANAGEMENT OF SEVERE TOXICITY: Refractory hypertension or hypertension with evidence of end organ dysfunction should be treated with sodium nitroprusside or phentolamine.  Hypotension may develop abruptly following hypertension, so a titratable agent is generally preferred.  Hypotension should initially be treated with intravenous fluid boluses.  If hypotension persists, a vasopressor such as dopamine or norepinephrine should be used unless they were involved in the overdose.  Ventricular tachycardias can be treated with lidocaine or amiodarone, and cardioversion if hemodynamically unstable.  If sinus tachycardia results in hemodynamic instability or cardiac strain, a short acting beta-blocker such as esmolol can be used, although care should be used as this may result in unopposed alpha-adrenergic stimulation. OCULAR EXPOSURE: Ocular exposure has occasionally caused systemic manifestations including transient hypertension, palpitations, tachycardia, ventricular ectopy, chest pain and in one case a non-ST elevation myocardial infarction.<\/li><li>Decontamination: PREHOSPITAL: There is no role for prehospital decontamination of a parenterally administered agent.  Irrigate eyes and mucous membranes, and wash skin as appropriate. HOSPITAL: There is no role for decontamination of a parenterally administered agent. Irrigate eyes and mucous membranes, and wash skin as appropriate.<\/li><li>Airway management: Patients who are comatose or with altered mental status may need orotracheal intubation and mechanical respiratory support.<\/li><li>Antidote: Phentolamine can be administered for intravenous extravasation of sympathomimetic agents.  Doses of 5 to 10 mg of phentolamine in 10 to 15 mL of normal saline can be infiltrated into the affected area.  Phentolamine has also been reportedly used successfully in accidental subcutaneous epinephrine injections that produce digit ischemia.  Doses of 0.5 to 1.5 mg injected either as a digital block or into the same site of the epinephrine injection have been reported. Intra-arterial infusion of phentolamine was used in one patient after inadvertent intra-arterial administration of epinephrine, with apparent success in reversing vasospasm and ischemia.<\/li><li>Enhanced elimination procedure: Hemodialysis is generally not useful since these agents have short half-lives.<\/li><li>Monitoring of patient: Drug levels are not clinically useful. Monitor vital signs frequently. Monitor serum electrolytes. Obtain cardiac enzymes for patients with chest pain. Obtain serial ECGs and institute continuous cardiac monitoring. Obtain a chest x-ray if there are signs or symptoms of pulmonary edema. Obtain a chest x-ray if there are signs or symptoms of pulmonary edema.<\/li><li>Patient disposition: HOME CRITERIA: Patients with accidental injections of epinephrine autoinjectors can generally be managed at home with warm soaks. OBSERVATION CRITERIA: Patients that do not manifest symptoms after 4 to 6 hours can be discharged. ADMISSION CRITERIA: Patients with unstable vital signs or evidence of end organ dysfunction should be admitted to an intensive care unit. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing severe poisonings.<\/li><\/ul>"},{"id":"464840-s-12-33","title":"Range of Toxicity","mono":"<b>SYMPATHOMIMETICS-PARENTERAL <\/b><br\/>TOXICITY: Varies depending on the agent. Toxic effects may occur at therapeutic doses while large doses have also resulted in no ill effects. Also depends on comorbid conditions as myocardial infarction has occurred with doses as little as 0.6 mg SubQ epinephrine. Fatalities have been reported at doses of 3 to 4 mg IV epinephrine. THERAPEUTIC DOSE: Varies depending on the agent. Epinephrine is typically given 0.3 mg IM or 1 mg IV to an adult. Norepinephrine is typically started as a drip at 4 mcg\/min IV to an adult. Phenylephrine is typically given 2 to 5 mg IM or 0.1 to 0.5 mg IV bolus to an adult.<br\/>"}]},"13":{"id":"464840-s-13","title":"Clinical Teaching","mono":"<ul><li>Patients taking oral form should avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness and somnolence.<\/li><li>Patients using ophthalmic form should not wear contact lenses during drug therapy.<\/li><li>Ophthalmic form may cause transient eye pain. Nasal form may cause nasal stinging\/burning or sneezing.<\/li><li>Patient should report signs\/symptoms of myocardial infarction, arrhythmia, and pulmonary edema.<\/li><li>Advise patient using ophthalmic form to report eye injury or signs\/symptoms of eye infection before taking next dose.<\/li><li>Teach patient proper administration technique, depending on route.<\/li><li>Patient should not use nasal form for more than 3 days, as prolonged use may cause rebound nasal congestion.<\/li><li>Tell patients using nasal form to avoid using other inhaled medicines through mouth\/nose unless approved by healthcare professional.<\/li><li>Patient should avoid giving oral form to children under 6 years old or rectal form to children under 12 years old unless approved by healthcare professional.<\/li><li>Advise patient to avoid using MAO inhibitors, antidepressants, or antihypertensive medication unless approved by healthcare professional.<\/li><\/ul>"}}}